Navigation Links
Keystone Dental to Pay Nobel Biocare $2 Million to Settle Unfair Competition, Trade Secret Violations, and Tortious Interference Lawsuit
Date:9/3/2008

YORBA LINDA, Calif., Sept. 3 /PRNewswire/ -- Nobel Biocare announced today it has reached a favorable settlement of a lawsuit brought against Keystone Dental, Inc., a dental implant company funded by the multi-billion dollar private equity firm Warburg Pincus, in the Superior Court of Connecticut. The settlement terms provide for Keystone Dental to pay $2 million to Nobel Biocare and that Keystone Dental not hire or solicit any current Nobel Biocare employee through February 1, 2009. Keystone Dental is also required to arrange for the collection and destruction of Nobel Biocare confidential and proprietary information in its or its employees' possession and represent that its employees will not use or disclose any marketing or sales materials licensed by and obtained from Nobel Biocare.

"Nobel Biocare stands for fair competition, but where competition crosses the line into illegality we will use all legal means to protect our proprietary information and trade secrets," stated Kevin Mosher, Vice President and General Manager of Nobel Biocare's North American business.

Nobel Biocare filed its lawsuit in late 2007 claiming that Keystone Dental systematically targeted and hired Nobel Biocare's sales and marketing employees who represented a full cross-section of Nobel Biocare's business and sales force. According to Nobel Biocare's lawsuit, Keystone Dental, in an attempt to gain an unfair competitive advantage, deliberately aided and abetted those employees to breach their noncompetition and confidentiality agreements with Nobel Biocare. The lawsuit further alleged that Keystone Dental and some of its employees failed to return confidential and proprietary information belonging to Nobel Biocare and that they were unlawfully using and disclosing Nobel Biocare's information and trade secrets to develop competitive products for Keystone Dental and to induce customers to terminate their contractual or business relationships with Nobel Biocare.

Nobel Biocare's lawsuit alleged Uniform Trade Secrets Act and Connecticut's Unfair Trade Practices Act violations, unfair competition, breach of contract, civil conspiracy to commit the tort of conversion/ misappropriation, breach of fiduciary duties, breach of duty of loyalty, conversion, and tortious interference with contractual and business relations. The lawsuit sought injunctive relief and compensatory and punitive damages.

Nobel Biocare is a medical devices group and the world leader in innovative esthetic dental solutions with its brands NobelActive(TM), Branemark System(R), NobelReplace(TM), NobelSpeedy(TM), NobelPerfect(R), NobelDirect(R), Replace Select (dental implants), Procera(R) (individualized dental prosthetics), NobelGuide(TM) (complete patient rehabilitation program) and NobelSmile(TM) (patient education and awareness program). Nobel Biocare is a full solution provider for restorative esthetic dentistry, offering a wide range of innovative Crown & Bridge & Implant products, as well as training and education, patient information and clinically documented treatment concepts. Nobel Biocare has over 2,500 employees and recorded revenue of EUR 665.9 million in 2007. The Company is domiciled and headquartered in Zurich, Switzerland. Production takes place at six production sites located in Sweden, the US, Japan and Israel. Nobel Biocare has 37 direct sales organizations. The shares of the parent company Nobel Biocare Holding AG are listed on the SWX Swiss Exchange.

http://www.nobelbiocare.com


'/>"/>
SOURCE Nobel Biocare
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. MB Software Corporation Reaches Agreement with Keystone Equity Partners
2. Temple University Hospital, Temple University School of Medicine and Crozer-Keystone Health System Collaborate to Provide Comprehensive Kidney Care
3. Keystone Human Services Acquires Impact Systems, Inc.
4. Keystone Programs for Collaborative Discovery Launch at Fox Chase
5. Phillipsburg Easton Honda to Host Miller-Keystone Blood Drive
6. Keystone Mercy and DVCH to Offer Screenings for National Health Center Week
7. Temple, Fox Chase and Geisinger create Keystone Institute for Translational Medicine
8. Delta Dental of Illinois Introduces Smile Smart For Your Health
9. Toms of Maine Tooth Floss Earns American Dental Associations Seal of Acceptance
10. Most comprehensive study of mercury in dental fillings begins
11. Guardians Dental Network Experiences Double-Digit Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... 2016 , ... David J. Dykeman , Ginger Pigott , and ... speak at DeviceTalks West, Dec. 12, 2016, at the Fairmont Newport Beach in California. ... firm’s global Life Sciences & Medical Technology Group have been featured speakers at every ...
(Date:12/8/2016)... ... December 08, 2016 , ... SunView Software aims ... employees that are both engaging and easy to use. Coming off the heels ... company revealed today its plans to roll out new AI-powered self-service enhancements to ...
(Date:12/8/2016)... ... December 08, 2016 , ... Catalent Pharma ... drugs, biologics and consumer health products, today announced that it had joined the ... as a non-profit organization to unite pharmaceutical and healthcare companies that share a ...
(Date:12/8/2016)... Dallas, TX (PRWEB) , ... December 08, 2016 , ... ... to continue to be a convenient service for Texas, they are expanding their presence ... will involve a hiring spree that will bring new jobs to the Dallas and ...
(Date:12/8/2016)... ... December 08, 2016 , ... Today’s patients are ... this in mind, SIGVARIS has created a new line of anti-embolism stockings to ... and provide the benefits of graduated compression when transitioning from recovery to early ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016  Valeant Pharmaceuticals ... TSX: VRX) ("Valeant") today announced positive results from ... study to assess the safety and efficacy of ... treatment of plaque psoriasis. Within ... with moderate to severe psoriasis, IDP-118 showed statistical ...
(Date:12/8/2016)... Mass. , Dec. 8, 2016  EIP ... it has obtained proof-of-mechanism for neflamapimod (previously code ... completed Phase 2a clinical trials that demonstrated significant ... Study 302 (12-week treatment) and Study 303 (6-week ... Clinical Trials in Alzheimer,s Disease (CTAD) scientific conference ...
(Date:12/8/2016)... , Dec. 8, 2016 A Small ... the National Institutes of Health (NIH) to ... University.  The grant will seek to ... head device, which utilizes electromagnetic waves to treat Alzheimer,s ... this novel technology to possibly treat other neurologic disorders ...
Breaking Medicine Technology: